RR6 prognostic model provides information about survival for myelofibrosis treated with ruxolitinib: validation in a real-life cohort
Emilia Scalzulli, Claudia Ielo, Cristina Luise, Paolo Musiu, Maria Laura Bisegna, Ida Carmosino, Giovanni Manfredi Assanto, Maurizio Martelli, Massimo Breccia
Topics & Concepts
RuxolitinibMyelofibrosisCohortPrognostic modelMedicineOncologySurvival analysisInternal medicineCohort studyOverall survivalBone marrowMyeloproliferative Neoplasms: Diagnosis and TreatmentKruppel-like factors researchEosinophilic Disorders and Syndromes